TABLE 5.

Comparison of the overall median of the included studies in the review of Tariman et al. and this review, concerning the percentage disconcordance and the disconcordance per level presented for all studies and for subgroups ¹⁴

	Previous review by Tariman et al.					Present review by Noteboom et al.
	Overall		Active	Shared	Passive	Overall		Active	Shared	Passive
Disconcordance	N = number of studies, participants, decisions a	Median % (IQR)	Median % (IQR)	Median % (IQR)	Median % (IQR)	N = number of studies, participants, decisions a	Median % (IQR)	Median % (IQR)	Median % (IQR)	Median % (IQR)
All	N = 14, 5054, 5255	38 (25–52)	39 (22–63)	67 (63–75)	37 (27–56)	N = 26, 12308, 15598	31 (22–44)	26 (18–41)	42 (26–59)	22 (14–40)
Breast	N = 10, 4443, 4644	38 (30–49)	30 (13–41)	65 (60–70)	41 (19–85)	N = 11, 3439, 3995	46 (31–60)	42 (20–67)	62 (27–74)	30 (16–53)
Lung	N = 1 b , 22, 22	29	‐	‐	‐	N = 2 b , 126, 126	32	25	35	29
							19	27	15	19
Haematologic	N = 0	‐	‐	‐	‐	N = 1 b , 268, 235	23	28	44	8
Colorectal	N = 1 b , 55, 55	69	100	85	32	N = 1 b , 113, 113	28	14	54	14
Prostate	N = 0	‐	‐	‐	‐	N = 2 b , 635, 635	17	11	‐	67
							3	1	3	10
Western	N = 14, 5054, 5255	38 (25–52)	39 (22–63)	67 (63–75)	37 (27–56)	N = 20, 11055, 14345	30 (21‐50)	27 (19‐42)	42 (27‐64)	21 (11‐52)
Asian	N = 0	‐	‐	‐	‐	N = 6, 1253, 1253	32 (23–42)	25 (12–48)	35 (12–50)	23 (14–33)
Early	N = 6, 2760, 2760	38 (31–51)	26 (range 9–34)	64 (range 58–66)	41 (range 40–100)	N = 10, 3105, 3661	44 (24–55)	37 (21–64)	62 (27–74)	36 (20–62)
Advanced	N = 1 b , 22, 22	29	‐	‐	‐	N = 4, 719, 695	31 (26–55)	25	37	20

^a Numbers are based on the overall disconcordance, numbers of studies, participants and decisions for the disconcordance of the active, shared or passive role might deviate from the numbers for the overall disconcordance, due to the incompleteness of the reported data in the individual studies.

^b For subgroups that include 1 or 2 studies, the individual percentage(s) is presented.